The 6 most recent market catalysts affecting $BEAM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics announced updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). The data showed promising eff…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD
Beam Therapeutics released updated, positive clinical data from its Phase 1/2 trial for BEAM-302, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The data highlig…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Beam Therapeutics shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $80 price target.
The reiteration of a 'Buy' rating and an $80 price target by HC Wainwright & Co. acts as a strong positive catalyst for Beam Therapeutics. This analyst endorsement signals confiden…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio has reaffirmed his 'Buy' rating and $80 price target for Beam Therapeutics. This action signals that the analyst's outlook on the co…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 95
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics announced Q2 results that fell significantly short of analyst estimates. The company reported a loss of $(1.18) per share against an estimate of $(1.11), and sale…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 55
Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026
Beam Therapeutics has announced a future event: the presentation of updated clinical data for its BEAM-302 program at the ERS Congress in September 2026. This is a forward-looking …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.